MilliporeSigma Develops New CRISPR Technology
The company developed proxy-CRISPR which provides access to previously unreachable areas of the genome.
On May 17, 2017 MilliporeSigma announced that it has developed a new CRISPR genome-editing tool. This new technique, called proxy-CRISPR, provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. Proxy-CRISPR increases their usability without the need to re-engineer native CRISPR proteins, the company noted in a press release. According to MilliporeSigma, the company has filed several patent applications on the proxy-CRISPR technology.
MilliporeSigma's research on proxy-CRISPR, Targeted Activation of Diverse CRISPR-Cas Systems for Mammalian Genome Editing via Proximal CRISPR Targeting, was published in the April 7, 2017 edition of Nature Communications. The article explains how to make CRISPR more efficient, flexible, and specific by opening the genome for the cutting of DNA, giving researchers more editing options.
The new technology is an addition to MilliporeSigma's existing CRISPR applications. The company's next suite of genome editing tools for the research community, to be launched later in 2017, will include novel and modified versions of Cas and Cas-like proteins.
Source: MilliporeSigma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
